<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03900325</url>
  </required_header>
  <id_info>
    <org_study_id>BRB-018-200DG</org_study_id>
    <nct_id>NCT03900325</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy of Nimacimab in Patients With Diabetic Gastroparesis</brief_title>
  <official_title>A Single-Blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy of Nimacimab in Patients With Diabetic Gastroparesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bird Rock Bio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bird Rock Bio, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single blind phase 2a study to evaluate the safety, tolerability, pharmacokinetics,
      and exploratory efficacy of nimacimab in patients with diabetic gastroparesis.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of clinically significant laboratory abnormalities</measure>
    <time_frame>Day 38</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of clinically significant vital signs</measure>
    <time_frame>Day 38</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of clinically significant ECGs</measure>
    <time_frame>Day 38</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nimacimab serum concentration</measure>
    <time_frame>Day 3, Day 8, Day 10, Day 38</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Measure rate of gastric emptying after ingestion of a radio-labeled meal as measured by gamma scans (scintigraphy) at 0, 0.5, 1, 2, 3, and 4 hours post meal</measure>
    <time_frame>Baseline, Day 10</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Gastric emptying half-time as measured by gamma scans (scintigraphy) after ingestion of a radio-labeled meal.</measure>
    <time_frame>Baseline, Day 10</time_frame>
    <description>Half time (t1/2) of gastric emptying (GE) of solids is the time for half of the ingested solids or liquids to leave the stomach.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary (GCSI-DD) Composite Score at 15 days</measure>
    <time_frame>Baseline and 15 days</time_frame>
    <description>The ANMS GCSI-DD composite score includes score of nausea, early satiety, upper abdominal pain and postprandial fullness. The severity scores of these symptoms range from 0 ( none) to 4 (very severe).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Diabetic Gastroparesis</condition>
  <arm_group>
    <arm_group_label>Nimacimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.5 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% sodium chloride</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nimacimab</intervention_name>
    <description>2.5 mg/kg</description>
    <arm_group_label>Nimacimab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% sodium chloride</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with type 1 or type 2 diabetes

          -  Diagnosed with diabetic gastroparesis, defined by:

               1. 3 month past or current history of symptoms of gastroparesis (e.g. nausea,
                  vomiting, bloating, abdominal pain, or feeling full earlier than normal after
                  eating)

               2. Screening or historical scintigraphy (3 years prior to screening) with &gt; 20% of
                  solid contents retained at 4 hours.

          -  BMI &gt;= 20.0 and &lt; = 50.0 kg/m2

        Exclusion Criteria:

          -  Participants on prokinetic therapy should have these medications withdrawn at least 7
             days prior to any study scintigraphy exam and at least 7 days prior to the first dose
             through Day 15 of treatment.

          -  Participants with any active prokinetic device are excluded, unless device is turned
             off for at least 7 days prior to any study scintigraphy exam and at least 7 days prior
             to the first dose through Day 15 of treatment.

          -  Participants who are currently participating in or have participated in a study of an
             investigational agent or has used an investigational device within 4 weeks prior to
             the first dose of study intervention.

          -  Participants with uncontrolled diabetes. Participants with controlled diabetes are
             allowed (insulin is allowed). HbA1c&gt;9.9% at screening are excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Panax Clinical Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Research Associates, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33183</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PRN of Kansas</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinSearch</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>March 27, 2019</study_first_submitted>
  <study_first_submitted_qc>April 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2019</study_first_posted>
  <last_update_submitted>January 14, 2020</last_update_submitted>
  <last_update_submitted_qc>January 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroparesis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

